PBT Share Price

Open 0.05 Change Price %
High 0.06 1 Day 0.00 0.00
Low 0.05 1 Week 0.00 0.00
Close 0.06 1 Month 0.00 0.00
Volume 126000 1 Year -0.06 -50.00
52 Week High 0.15
52 Week Low 0.05
PBT Important Levels
Resistance 2 0.07
Resistance 1 0.07
Pivot 0.06
Support 1 0.05
Support 2 0.05
ASX Australia Most Active Stocks
AKK 0.01 0.00%
GPP 0.03 0.00%
IMU 0.01 0.00%
IMU 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
DUE 2.74 16.60%
DUE 2.74 16.60%
PDN 0.06 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
AHN 0.04 100.00%
AZS 0.03 50.00%
AZS 0.03 50.00%
PMQ 0.03 50.00%
NGY 0.05 25.00%
BIT 0.05 25.00%
BIT 0.05 25.00%
RAW 0.06 20.00%
RAW 0.06 20.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
BMN 0.02 -33.33%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
AZM 0.03 -25.00%
NMS 0.90 -23.73%
More..

Prana Biotechnology Ltd (ASX: PBT)

PBT Technical Analysis 5
As on 5th Dec 2016 PBT Share Price closed @ 0.06 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.09 & Strong Sell for SHORT-TERM with Stoploss of 0.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
PBT Target for December
1st Target up-side 0.06
2nd Target up-side 0.07
3rd Target up-side 0.08
1st Target down-side 0.04
2nd Target down-side 0.03
3rd Target down-side 0.02
PBT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.pranabio.com
PBT Address
PBT
369 Royal Parade
Level 2
Parkville, VIC 3052
Australia
Phone: 61 3 9349 4906
Fax: 61 3 9348 0377
PBT Latest News
Interactive Technical Analysis Chart Prana Biotechnology Ltd ( PBT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Prana Biotechnology Ltd
PBT Business Profile
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimer‘s, Parkinson‘s, and Huntington‘s diseases, as well as various cancer and age-related macular degeneration. The company’s product line includes PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer’s disease, as well as in Phase IIa clinical trials to treat Huntington’s disease. Its preclinical products comprise PBT434 for the treatment of Alzheimer’s disease; and PBT519 to treat brain cancer. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.